| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05372640 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694… |
date change Primary completion pushed: 2026-06-01 -> 2027-06-07 |
| 2026-06-12 | NCT05372640 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694… |
date change Completion pushed: 2026-06-01 -> 2027-06-07 |
| 2026-06-12 | NCT07604272 Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal… |
Enrollment reduced: 75 -> 30 participants |
| 2026-06-12 | NCT07604272 Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal… |
Trial arms changed: 3 -> 2 |
| 2026-06-12 | NCT06982521 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for… |
Trial sites expanded: 158 -> 192 locations |
| 2026-06-10 | NCT07368998 To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With… |
Trial sites expanded: 19 -> 26 locations |
| 2026-06-09 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-09 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
Trial sites expanded: 13 -> 25 locations |
| 2026-06-06 | NCT01953588 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III… |
Primary endpoint(s) modified |
| 2026-06-05 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-05 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
Trial sites reduced: 25 -> 13 locations |
| 2026-06-05 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 324 -> 327 locations |
| 2026-06-04 | NCT07226349 A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced… |
Trial sites expanded: 18 -> 21 locations |
| 2026-06-04 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 4 -> 13 locations |
| 2026-06-03 | NCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants… |
Enrollment reduced: 234 -> 210 participants |
| 2026-06-02 | NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With… |
Enrollment reduced: 258 -> 103 participants |
| 2026-06-02 | NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With… |
date change Primary completion moved earlier: 2028-04 -> 2026-08-31 |
| 2026-06-02 | NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With… |
date change Completion moved earlier: 2028-07 -> 2026-08-31 |
| 2026-05-30 | NCT02693535 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a… |
Trial sites expanded: 174 -> 181 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-01 | NCT07619066 A Phase II Study of Zongertinib Plus Fulvestrant in Participants With… | Phase 2 | Not Yet Recruiting |
| 2026-05-22 | NCT07604272 Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal… | Phase 1 | Not Yet Recruiting |
| 2026-05-22 | NCT07604571 Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2… | Phase 1 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06169371 | Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) | Breast Cancer | Recruiting |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | Metastatic Breast Cancer | Active, Not Recruiting |
| Phase 3 | |||
| NCT07207070 | A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy… | Breast Cancer | Recruiting |
| NCT07024173 | A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and… | Locally Advanced Breast Cancer | Recruiting |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… | Breast Cancer | Recruiting |
| NCT06954961 | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic… | Breast Cancer | Recruiting |
| NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With… | Breast Cancer | Recruiting |
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine… | Advanced Breast Cancer | Recruiting |
| NCT04862663 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer… | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Recruiting |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… | HR+/HER2- Breast Cancer | Recruiting |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Recruiting |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… | Breast Neoplasms | Recruiting |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for… | PIK3CA Mutation | Recruiting |
| NCT05365178 | To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus… | HR-positive, HER2-negative Breast Neoplasms | Active, Not Recruiting |
| NCT04584853 | PreOperative Endocrine Therapy for Individualised Care With Abemaciclib | Breast Cancer Female | Active, Not Recruiting |
| NCT05169567 | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in… | Breast Neoplasm | Active, Not Recruiting |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in… | Breast Cancer | Active, Not Recruiting |
| NCT02763566 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the… | Breast Cancer | Active, Not Recruiting |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat… | HER-2 Positive Breast Cancer | Active, Not Recruiting |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in… | Advanced Breast Cancer | Active, Not Recruiting |
| NCT06635447 | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic… | Breast Cancer | Active, Not Recruiting |
| NCT04851613 | Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With… | Breast Cancer | Active, Not Recruiting |